Current Status of COVID‐19 (Pre)Clinical Vaccine Development - Ye - 2020 - Angewandte Chemie International Edition - Wiley Online Library
PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
Moderna Therapeutics — Wikipédia
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
Moderna's coronavirus vaccine shows encouraging early results - The Washington Post
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moncef Slaoui - Wikipedia
PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
